Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Sandy Amorim, Isabelle Fleury, Nicolas Mounier, Stéphanie Harel, Pauline Brice & Catherine Thieblemont. (2016) Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment. Leukemia & Lymphoma 57:10, pages 2425-2428.
Read now
Read now
Mariam Jamal-Hanjani & Ruth Pettengell. (2011) Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1441-1448.
Read now
Read now
Articles from other publishers (11)
Manmeet Kaur, Mandeep Kaur, Tania Bandopadhyay, Aditi Sharma, Anu Priya, Arvind Singh & Bubun Banerjee. (2023) Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. Physical Sciences Reviews 8:10, pages 3393-3446.
Crossref
Crossref
Francesco Malaspina, Cinzia Pellegrini, Beatrice Casadei, Lisa Argnani & Pier Luigi Zinzani. (2017) Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma. Acta Haematologica 137:4, pages 191-194.
Crossref
Crossref
Pier Luigi Zinzani, Paolo Corradini, Maurizio Martelli, Giorgio Minotti, Stefano Oliva, Michele Spina, Giovanni Barosi & Sante Tura. (2016) Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper. European Journal of Haematology 97:6, pages 554-561.
Crossref
Crossref
B. B. Hasinoff, X. Wu, D. Patel, R. Kanagasabai, S. Karmahapatra & J. C. Yalowich. (2015) Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase II Isoform. Journal of Pharmacology and Experimental Therapeutics 356:2, pages 397-409.
Crossref
Crossref
Hong X. Ding, Carolyn A. Leverett, Robert E. KyneJr.Jr., Kevin K.-C. Liu, Subas M. Sakya, Andrew C. Flick & Christopher J. O’Donnell. (2014) Synthetic approaches to the 2012 new drugs. Bioorganic & Medicinal Chemistry 22:7, pages 2005-2032.
Crossref
Crossref
Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth & J. Robert Merritt. 2013.
471
546
.
W.A. Denny. 2013. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Christophe Wiart. 2013. Lead Compounds from Medicinal Plants for the Treatment of Cancer. Lead Compounds from Medicinal Plants for the Treatment of Cancer
267
380
.
Ruth Pettengell, Bertrand Coiffier, Geetha Narayanan, Fernando Hurtado de Mendoza, Raghunadharao Digumarti, Henry Gomez, Pier Luigi Zinzani, Gary Schiller, David Rizzieri, Giles Boland, Paul Cernohous, Lixia Wang, Christine Kuepfer, Igor Gorbatchevsky & Jack W Singer. (2012) Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. The Lancet Oncology 13:7, pages 696-706.
Crossref
Crossref
Paul A. Fields & David C. Linch. (2012) Treatment of the elderly patient with diffuse large B cell lymphoma. British Journal of Haematology 157:2, pages 159-170.
Crossref
Crossref
Benny J. Evison, Mile Pastuovic, Rebecca A. Bilardi, Robert A. Forrest, Paul P. Pumuye, Brad E. Sleebs, Keith G. Watson, Don R. Phillips & Suzanne M. Cutts. (2011) M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe. Biochemical Pharmacology 82:11, pages 1604-1618.
Crossref
Crossref